AlectorALEC
About: Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Employees: 241
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
61% more call options, than puts
Call options by funds: $698K | Put options by funds: $433K
0% more funds holding
Funds holding: 159 [Q2] → 159 (+0) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 21
2% less capital invested
Capital invested by funds: $344M [Q2] → $338M (-$5.21M) [Q3]
6% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 50
3.98% less ownership
Funds ownership: 78.53% [Q2] → 74.55% (-3.98%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Morgan Stanley Matthew Harrison 38% 1-year accuracy 6 / 16 met price target | 52%upside $3 | Underweight Downgraded | 26 Nov 2024 |
BTIG Thomas Shrader 20% 1-year accuracy 1 / 5 met price target | 154%upside $5 | Buy Maintained | 26 Nov 2024 |
HC Wainwright & Co. Andrew Fein 37% 1-year accuracy 78 / 211 met price target | 1,677%upside $35 | Buy Reiterated | 7 Nov 2024 |
Financial journalist opinion
Based on 5 articles about ALEC published over the past 30 days